Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low Dose Estriol Vaginal Gel for Vaginal Dryness
NCT02967510Phase 2Completed
- Sponsor
- ITF Research Pharma
- Start
- Oct 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of estriol in Vulvovaginal atrophy (VVA) (4 arms), sponsored by ITF Research Pharma. Primary endpoints: Change From Baseline in the Severity of Vaginal Dryness at 3 weeks, Change From Baseline in Vaginal pH at 3 weeks and 2 more. Started Oct 2016; status: completed.
02
Drugs
estriol
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT02967510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967510.